HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Performance Characteristics of Galactomannan and β-d-Glucan in High-Risk Liver Transplant Recipients.

AbstractBACKGROUND:
The utility of Aspergillus galactomannan (GM) and β-D-glucan (BG) in liver transplant recipients remains uncertain.
METHODS:
As part of a randomized, double-blind trial of antifungal prophylaxis in liver transplant recipients at risk for invasive fungal infections (IFIs), GM and BG were assessed in 199 patients at baseline (enrollment) and weekly thereafter for the duration of study drug. Receiver operating characteristic (ROC) analysis was used to evaluate the accuracy of these for the diagnosis of IFIs.
RESULTS:
Overall, 46.4% of the patients at baseline had positive GM (index ≥ 0.5) and 89.6% had BG of 80 pg/mL or greater with BG level of 500 pg/mL or greater in 31.8%. Patients with invasive aspergillosis (IA) (3/3) had positive GM at baseline as did 45.5% of those without IA (P = 0.098); the area under the ROC curve for the diagnosis of IA was 0.77 (fair test, ie, good sensitivity but poor specificity). Using BG cutoff of 80 pg/mL or higher, 100% (12/12) of the patients with IFI had positive baseline BG and as did 88.9% (160/180) of those without IFI (P = 0.618); the area under the ROC curve for predicting IFIs was 0.56 (poor test). In multivariate analyses, GM positivity was associated with study site (P = 0.041), and BG positivity with renal replacement therapy (P = 0.05) and study site (P = 0.01). The GM and BG levels declined over time; positivity at subsequent time points was lower in comparison with baseline (P < 0.001).
CONCLUSIONS:
The GM and BG tests had significant center variability and limited accuracy for the diagnosis of IFIs in high-risk liver transplant recipients.
AuthorsNina Singh, Drew J Winston, Ajit P Limaye, Shawn Pelletier, Nasia Safdar, Michele I Morris, Katherine Meneses, Ronald W Busuttil, Marilyn M Wagener, L Joseph Wheat
JournalTransplantation (Transplantation) Vol. 99 Issue 12 Pg. 2543-50 (Dec 2015) ISSN: 1534-6080 [Electronic] United States
PMID26050015 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antifungal Agents
  • Mannans
  • Proteoglycans
  • beta-Glucans
  • galactomannan
  • polysaccharide-K
  • Galactose
Topics
  • Adult
  • Aged
  • Antifungal Agents (therapeutic use)
  • Aspergillosis (drug therapy, etiology)
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Galactose (analogs & derivatives)
  • Humans
  • Liver Transplantation
  • Male
  • Mannans (metabolism)
  • Middle Aged
  • Postoperative Complications (metabolism, prevention & control)
  • Prospective Studies
  • Proteoglycans
  • ROC Curve
  • Risk Factors
  • Young Adult
  • beta-Glucans (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: